Veradigm Inc. · OTC:MDRX

Veradigm — Barclays Healthcare Investor Conference 2024

11 slides from Veradigm's conference presentation, Mar 13, 2024

  1. Slide 1: Barclays Healthcare Investor Conference

    Barclays Healthcare Investor Conference Veradigm Miami, Florida | March 13, 2024 Exhibit 99.2

  2. Slide 2: Disclaimer & Forward-Looking Statements

    Disclaimer & Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, expected financial results for fiscal 2024 and beyond, statement

  3. Slide 3: Reset. Reinvest. Renew Growth. Mission Positioning

    Reset. Reinvest. Renew Growth. Dr. Yin Ho, Interim CEO Mission Positioning

  4. Slide 4: Veradigm at the intersection of the three pillars of healthcare

    Veradigm’s established technology platforms and solutions place it at the intersection of the three pillars of healthcare. Providers Large ambulatory footprint and 25 years of EMR records has created the Veradigm Network spanning 400K+ Providers and 200M+ Patient records payErs Life sciences Large c

  5. Slide 5: Healthcare Marketplace Converging Around Data Intelligence

    Care primarily happens in ambulatory settings Staying on top of changing interoperability standards Payers and providers need data to meet value-based requirements and purchasing Dynamic regulatory environment warrants leadership Expanding use of real-world data Supporting health economics outcomes

  6. Slide 6: Reset. Reinvest. Renew Growth. State of Veradigm

    Reset. Reinvest. Renew Growth. Lee Westerfield, Interim CFO State of Veradigm Invest for Growth & Profitability Financial Guidance and Outlook

  7. Slide 7: State of Veradigm

    Ample liquidity. Net Cash1 position of ~$140M. Resilient profitability. Steady normalized adjusted EBITDA margins. Temporary opex bolus in 2024. Scale advantage surrounds EHR Approximately 400K providers and 200 million clinical records. Advantageous health data. Sourced from our network. Delisted.

  8. Slide 8: Financial Impact in 2024 and Beyond

    Financial Impact in 2024 and Beyond INITIATIVES & INVESTMENTS IN 2024 Reinvestment in 2024 for Future Growth & Margin Expansion In 2024, Payer & Life Sciences (PLS) drives growth. AI data pilots in Q4. For 2025-26, potential revenue growth to accelerate to 10%+ CAGR with gross margin expansion as hi

  9. Slide 9: Guidance and Outlook

    Guidance and Outlook Financials Outlook Beyond 2024 Annual Guidance Range for 2024 ($M) 1 From the mid point of the F2023 estimated ranges published 1.10.24. 2 A non-GAAP financial measure. Please refer to the Appendix. Revenue, GAAP $620M - $635M Growth of ~1 - 3% in 20241 Adjusted EBITDA2 $104M -

  10. Slide 10: Thank You

    Thank You veradigm.

  11. Slide 11: Appendix

    Appendix Veradigm reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Veradigm presents Adjusted EBITDA, which is considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchang

Veradigm — Barclays Healthcare Investor Conference 2024 on 6ix